立体定向消融放疗治疗早期非小细胞肺癌后复发模式与危险因素的竞争风险分析
回顾性分析1068例不可手术早期非小细胞肺癌患者共1143个病灶接受立体定向消融放疗后的复发模式,中位随访37.6个月,中央位置是局部复发和区域复发的唯一独立危险因素,首次复发后接受第二程SABR者总生存优于系统治疗和支持治疗。
要点
- 中央位置是局部复发(p=0.016)和区域复发(p=0.005)的唯一独立危险因素。
- 超中央位置与区域复发(p=0.004)和远处转移(p=0.01)风险升高相关。
- 首次复发后接受第二程SABR者总生存51.3个月,优于系统治疗19.5个月和支持治疗8.1个月(p<0.0001)。
核心结论
- 局部复发和区域复发的主要预后因素为中央位置。
- 超中央和中央肿瘤可能从剂量递增和/或联合系统治疗等治疗强化策略中获益以改善放疗结局。
- SABR后首次复发,对侧肺复发者和适合接受第二程SABR者总生存改善。
研究设计与样本
- 回顾性分析纳入1068例早期非小细胞肺癌患者共1143个病灶,采用竞争风险分析评估组间差异并计算病因特异性风险比。
主要发现
- 中位随访37.6个月。
- 单因素分析显示超中央位置与区域复发风险升高相关(p=0.004)且与远处转移风险升高相关(p=0.01)。
- 中央病灶与局部复发风险升高相关(p<0.001)且与区域复发风险升高相关(p<0.001)。
- 超中央病灶较周围病灶总生存更短(p=0.002)。
- 多因素分析中中央位置是唯一与局部复发风险升高(p=0.016)和区域复发风险升高(p=0.005)相关的因素。
临床怎么用
- 超中央和中央肿瘤可能从剂量递增和/或联合系统治疗等治疗强化策略中获益以改善放疗结局(作者认为)。
- SABR后首次复发,对侧肺复发者和适合接受第二程SABR者总生存改善(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To assess patterns of recurrence after stereotactic ablative radiotherapy (SABR) in patient ineligible to surgery with early-stage non-small cell lung cancer (ES-NSCLC), report survival and treatment after first recurrence. METHODS: We performed a retrospective analysis on 1068 patients with ES-NSCLC and 1143 lesions. Between group differences were estimated using competing risk analysis and cause-specific hazard ratios were calculated. Overall survival (OS) after first recurrence was calculated. RESULTS: Median follow-up was 37.6 months. Univariate analysis demonstrated that ultra-central location was associated with higher risk of regional recurrence (RR) and distant metastasis (DM) (p = 0.004 and 0.01). Central lesions were associated with higher risk of local recurrence (LR) and RR (p < 0.001). Ultra-central lesions were associated with shorter OS (p = 0.002) compared to peripheral lesions. In multivariate analysis, central location was the only factor associated with increased LR and RR risks (p = 0.016 and 0.005). Median OS after first recurrence was 14.8 months. There was no difference in OS after first recurrence between ultra-central, central, and peripheral lesions (p = 0.83). Patients who received a second SABR course had an OS of 51.3 months, compared to 19.5 months with systemic therapy and 8.1 months with supportive care (p < 0.0001). DISCUSSION: The main prognostic factor for LR and RR risks was central location. Ultra-central and central tumors might benefit from treatment intensification strategies such as dose escalation and/or addition of systemic therapy to improve radiotherapy outcomes. After a first recurrence post SABR, patients with contralateral lung recurrences and those who were eligible to receive a second course of SABR had improved OS.
引用
- Tonneau M, Richard C, Routy B, et al. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Radiother Oncol. 2023. PMID: 37169303. doi:10.1016/j.radonc.2023.109697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。